Cargando…
MODL-11. COMPARISON OF HUMAN & MURINE PA/PXA CHARACTERISTICS
Pediatric low-grade gliomas (pLGGs) are the most common brain tumors in children. Despite recent advances in the molecular characterization of this heterogeneous set of tumors, the separation of specific tumor types is still not fully established. Pilocytic astrocytoma (PA; WHO grade I) and pleomorp...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715598/ http://dx.doi.org/10.1093/neuonc/noaa222.585 |
_version_ | 1783618993043537920 |
---|---|
author | Sommerkamp, Alexander C Sun, Pengbo Wefers, Annika K Ismer, Britta Schramm, Kathrin Wittmann, Andrea Gronych, Jan Korshunov, Andrey von Deimling, Andreas Jäger, Natalie Pfister, Stefan M Jones, David T W |
author_facet | Sommerkamp, Alexander C Sun, Pengbo Wefers, Annika K Ismer, Britta Schramm, Kathrin Wittmann, Andrea Gronych, Jan Korshunov, Andrey von Deimling, Andreas Jäger, Natalie Pfister, Stefan M Jones, David T W |
author_sort | Sommerkamp, Alexander C |
collection | PubMed |
description | Pediatric low-grade gliomas (pLGGs) are the most common brain tumors in children. Despite recent advances in the molecular characterization of this heterogeneous set of tumors, the separation of specific tumor types is still not fully established. Pilocytic astrocytoma (PA; WHO grade I) and pleomorphic xanthoastrocytoma (PXA; WHO grade II) are two pLGG types that can be difficult to distinguish based on histology alone. Even though their clinical course is different, they are often grouped as ‘pLGG’ in clinical trials (and therefore treated similarly). Based on a cohort of 89 human pediatric tumor samples, we show that PAs and PXAs have clearly distinct methylation and transcriptome profiles. The difference in gene expression is mainly caused by cell cycle- and development-associated genes, suggesting a key difference in the regulatory circuits involved in tumor growth. In addition to BRAF V600E, we found NTRK fusions and a previously unknown EGFR:BRAF fusion as mutually exclusive driving events in PXAs. Both tumor types show marked signs of immune cell infiltration, but with significant qualitative differences, which might represent therapeutic vulnerabilities. To pave the way for further research on PA and PXA, we developed corresponding mouse models using the virus-based RCAS system, which allows introduction of an oncogenic driver into immunocompetent mice for molecular and preclinical research. The murine tumors do not only histologically resemble their human counterparts but also show a similar growth behavior. Expression analysis revealed that the murine PXAs have a stronger gene signature of proliferation and immune cell infiltration compared to PAs. |
format | Online Article Text |
id | pubmed-7715598 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-77155982020-12-09 MODL-11. COMPARISON OF HUMAN & MURINE PA/PXA CHARACTERISTICS Sommerkamp, Alexander C Sun, Pengbo Wefers, Annika K Ismer, Britta Schramm, Kathrin Wittmann, Andrea Gronych, Jan Korshunov, Andrey von Deimling, Andreas Jäger, Natalie Pfister, Stefan M Jones, David T W Neuro Oncol Preclinical Models/Experimental Therapy/Drug Discovery Pediatric low-grade gliomas (pLGGs) are the most common brain tumors in children. Despite recent advances in the molecular characterization of this heterogeneous set of tumors, the separation of specific tumor types is still not fully established. Pilocytic astrocytoma (PA; WHO grade I) and pleomorphic xanthoastrocytoma (PXA; WHO grade II) are two pLGG types that can be difficult to distinguish based on histology alone. Even though their clinical course is different, they are often grouped as ‘pLGG’ in clinical trials (and therefore treated similarly). Based on a cohort of 89 human pediatric tumor samples, we show that PAs and PXAs have clearly distinct methylation and transcriptome profiles. The difference in gene expression is mainly caused by cell cycle- and development-associated genes, suggesting a key difference in the regulatory circuits involved in tumor growth. In addition to BRAF V600E, we found NTRK fusions and a previously unknown EGFR:BRAF fusion as mutually exclusive driving events in PXAs. Both tumor types show marked signs of immune cell infiltration, but with significant qualitative differences, which might represent therapeutic vulnerabilities. To pave the way for further research on PA and PXA, we developed corresponding mouse models using the virus-based RCAS system, which allows introduction of an oncogenic driver into immunocompetent mice for molecular and preclinical research. The murine tumors do not only histologically resemble their human counterparts but also show a similar growth behavior. Expression analysis revealed that the murine PXAs have a stronger gene signature of proliferation and immune cell infiltration compared to PAs. Oxford University Press 2020-12-04 /pmc/articles/PMC7715598/ http://dx.doi.org/10.1093/neuonc/noaa222.585 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Preclinical Models/Experimental Therapy/Drug Discovery Sommerkamp, Alexander C Sun, Pengbo Wefers, Annika K Ismer, Britta Schramm, Kathrin Wittmann, Andrea Gronych, Jan Korshunov, Andrey von Deimling, Andreas Jäger, Natalie Pfister, Stefan M Jones, David T W MODL-11. COMPARISON OF HUMAN & MURINE PA/PXA CHARACTERISTICS |
title | MODL-11. COMPARISON OF HUMAN & MURINE PA/PXA CHARACTERISTICS |
title_full | MODL-11. COMPARISON OF HUMAN & MURINE PA/PXA CHARACTERISTICS |
title_fullStr | MODL-11. COMPARISON OF HUMAN & MURINE PA/PXA CHARACTERISTICS |
title_full_unstemmed | MODL-11. COMPARISON OF HUMAN & MURINE PA/PXA CHARACTERISTICS |
title_short | MODL-11. COMPARISON OF HUMAN & MURINE PA/PXA CHARACTERISTICS |
title_sort | modl-11. comparison of human & murine pa/pxa characteristics |
topic | Preclinical Models/Experimental Therapy/Drug Discovery |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715598/ http://dx.doi.org/10.1093/neuonc/noaa222.585 |
work_keys_str_mv | AT sommerkampalexanderc modl11comparisonofhumanmurinepapxacharacteristics AT sunpengbo modl11comparisonofhumanmurinepapxacharacteristics AT wefersannikak modl11comparisonofhumanmurinepapxacharacteristics AT ismerbritta modl11comparisonofhumanmurinepapxacharacteristics AT schrammkathrin modl11comparisonofhumanmurinepapxacharacteristics AT wittmannandrea modl11comparisonofhumanmurinepapxacharacteristics AT gronychjan modl11comparisonofhumanmurinepapxacharacteristics AT korshunovandrey modl11comparisonofhumanmurinepapxacharacteristics AT vondeimlingandreas modl11comparisonofhumanmurinepapxacharacteristics AT jagernatalie modl11comparisonofhumanmurinepapxacharacteristics AT pfisterstefanm modl11comparisonofhumanmurinepapxacharacteristics AT jonesdavidtw modl11comparisonofhumanmurinepapxacharacteristics |